AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Inclusion Criteria:

• Participant is willing to withhold his/her IOP (Intraocular Pressure) treatmentsaccording to the study requirements, and in the opinion of the investigator, can doso without significant risk.

• Diagnosis of either OAG [open-angle glaucoma] (ie, [POAG], pseudoexfoliationglaucoma,pigmentary glaucoma) or OHT (ocular hypertension) in both eyes.

• Must be pseudophakic (at least 4 months postcataract surgery prior to treatmentadministration [Cycle 1 Day 1 Administration visit]) (Cohort 3 only).

Exclusion Criteria:

• Known allergy or sensitivity to any study medication or its components, anycomponent of the delivery vehicle, procedure-related materials, or diagnostic agentsused during the study (eg, topical anesthetic, dilating drops, fluorescein,povidone-iodine).

• Concurrent or anticipated enrollment in an investigational drug or device study orparticipation in such a study within 2 months prior to the Baseline visit throughthe final study visit.

• History of intracameral implant in the study eye (eg, Bimatoprost SR, OTX-TIC,ENV515 Travoprost XR).

• History of laser trabeculoplasty within 6 months prior to screening in the studyeye.

• History or evidence of clinically relevant, substantial ocular trauma (eg, atraumatic cataract, traumatic angle recession, etc.) in the study eye.

• History or evidence of complicated cataract/lens surgery, as stated in the protocol.

• Intraocular surgery (including cataract surgery) in the study eye within the 4months prior to treatment administration.

• Any history of corneal graft, including partial grafts (eg, Descemet's StrippingEndothelial Keratoplasty [DSEK], Descemet's Membrane Endothelial Keratoplasty [DMEK]); or incisional refractive surgery (eg, radial keratotomy), other thanastigmatic keratotomy or limbal relaxing incisions in the study eye.

• History of herpetic ocular diseases in either eye (including herpes simplex virusand varicella zoster virus).

• Anticipated need for any incisional or laser ocular surgery in either eye during thestudy.

• History of anatomically narrow angle resulting in evidence of angle changes or anyhistory or closed angle glaucoma in the study eye.

• History or evidence of a peripheral iridotomy/iridectomy in the inferior iris in thestudy eye.

• Any history of trabeculectomy or other types of incisional glaucoma surgery,including a glaucoma seton or aqueous bypass stents in either eye, or minimallyinvasive glaucoma surgery (MIGS) type trabecular meshwork surgeries in the studyeye.

• Anticipated use of corticosteroids in either eye except for permitted interventionsor systemically during the study, or historical use prior to Baseline within:

• 3 years: intraocular fluocinolone acetonide

• 6 months: intraocular corticosteroid(s) other than fluocinolone; any injectableperiocular or sub-Tenon's/subconjunctival corticosteroid

• 2 months: systemic (eg, oral, intramuscular, intravenous) or topical ocularcorticosteroids

• 2 weeks: dermal corticosteroids applied to skin of the eyelid(s), around theeye, or adnexa.

• Anticipated use of other topical ocular medications in either eye except forpermitted interventions.

• The anticipated wearing of contact lenses in the study eye (Cohort 1) and both eyes (Cohorts 2 and 3) during the study that deviates from the following (contact lenswear is allowed during the study, but is to be temporarily discontinued before studyvisits, and before and after an Administration Day according to the following):

• Use of soft lenses should be discontinued at least 3 days prior to Baseline,and use of rigid gas permeable or hard contact lenses should be discontinued atleast 1 week prior to Baseline

• Use of soft lenses should be discontinued at least 3 days and use of rigid gaspermeable or hard contact lenses should be discontinued at least 1 week priorto a scheduled study visit or Administration Day visit

• Use of contact lenses of any kind should be discontinued for 1 week followingany AGN-193408 SR administration

• Central corneal thickness of < 480 or > 620 micrometers in both eyes.

• Visual field loss in the study eye that, in the opinion of the investigator, isfunctionally significant (eg, split fixation, field defect within the central 10degrees that is visually significant or likely to cause central visual impairmentupon progression) or shows evidence of progressive visual field loss within the yearprior to Baseline.

• Evidence of macular edema in either eye during screening or in participant's medicalhistory.

• At Screening, evidence of posterior synechia behind the iris inferiorly in the studyeye that in the investigator's opinion may inhibit the ability to safely receive atleast 1 AGN-193408 SR implant (Cohort 3 only).